Pediatric Targeted Therapy denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pediatric targeted therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Limits Quantities for Pediatric Targeted Therapy — and How to Appeal

Quantity-limit denials for pediatric targeted therapies often arise because BCBS's clinical coverage policy ties approved dispensing amounts to the dosing regimen specified in the FDA-approved prescribing information. When a child's weight, body-surface area, or tolerability profile leads the oncologist or specialist to prescribe an amount that falls outside a pre-set dispensing parameter, an automated quantity-limit flag is triggered — even when the prescription is clinically appropriate.

### Why This Denial Is Appealable

Quantity-limit policies must be grounded in the drug's FDA-approved labeling. If your child's prescriber has ordered a quantity that corresponds to the labeled dosing instructions (adjusted for the patient's specific characteristics as directed in the label), the denial is built on a mismatch between the insurer's static limit and the label's own weight- or body-surface-area-based guidance. That mismatch is a strong basis for reversal.

### Federal Appeal Framework

• Internal appeal: File within the deadline stated in your denial letter (typically 180 days for ERISA plans). BCBS must respond within 30 days for non-urgent requests or 72 hours for urgent/expedited requests.
• External review (ACA §2719 / ERISA §503): If the internal appeal fails, you have the right to an independent external review by an accredited Independent Review Organization (IRO). The window to request external review is generally 4 months from the final internal denial. For life-threatening pediatric conditions, request expedited external review, which carries a 72-hour turnaround.

### Documentation to Gather

1. Diagnosis confirmation — pathology report, imaging, or specialist evaluation confirming the covered diagnosis. 2. Prescribing rationale — a letter from the treating specialist explaining how the prescribed quantity aligns with the FDA label's weight- or BSA-based dosing table for this child's current measurements. 3. Current measurements on file — the chart note documenting the weight or body-surface area used to calculate the quantity. 4. Denial letter + plan's quantity-limit policy — request the specific coverage policy number and the clinical criteria used to set the limit.

### Criteria-Mapping Structure

Create a two-column table. In the left column, list every requirement from BCBS's published quantity-limit criteria (request the full policy in writing if not attached to the denial). In the right column, cite the exact chart fact or label reference that satisfies each requirement. For the quantity itself, show the arithmetic: patient weight or BSA × labeled dose frequency = total units needed, demonstrating that the prescribed quantity is the labeled quantity.

### Practical Next Step

Ask the prescriber's office to draft a medical-necessity letter that walks through the labeling calculation, references the applicable professional society guideline (e.g., relevant pediatric oncology society recommendations), and explicitly states that any lower quantity would result in under-dosing with clinically meaningful consequences for this child.